Science

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Rating Reaffirmed by Cann

Equities research analysts forecast that Editas Medicine will post ($3.04) earnings per share for the current fiscal year.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 6, and a price to sales ratio of 4.88.

Editas Medicine, Inc. (EDIT) failed to surprise the stock market in its last reported earnings when it earned -$0.85 a piece versus the consensus-estimated -$0.61. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.01. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $2.20 million. The return on equity ratio or ROE stands at -63.3 percent while most common profitability ratio return on investment (ROI) was -54.1 percent. The firm's quarterly revenue was down 8.8% compared to the same quarter a year ago. Next quarter's EPS is estimated at $-0.71 and the next full year EPS is anticipated to be $-3.18.

COPYRIGHT VIOLATION NOTICE: "Editas Medicine, Inc. (NASDAQ:EDIT) Expected to Announce Quarterly Sales of $2.88 Million" was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another website, it was stolen and reposted in violation of USA & worldwide copyright and trademark law. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/08/10/editas-medicine-inc-nasdaqedit-given-a-27-00-price-target-by-j-p-morgan-chase-co-analysts.html.

Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut Editas Medicine from a "buy" rating to a "hold" rating in a report on Tuesday, July 18th. They issued a "buy" rating on the stock. SunTrust Banks, Inc. assumed coverage on Editas Medicine in a research note on Thursday, July 13th. The longer the bull market run, the tougher the investing decisions might be for the stock picker. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The company presently has a consensus rating of Buy and an average target price of $25.03.

Editas Medicine (EDIT) opened at 17.98 on Wednesday. The company's market capitalization is $644.33 million. This indicator compares the closing price of a stock in relation to the highs and lows over a certain time period. The firm's 50 day moving average is $16.99 and its 200 day moving average is $18.99. State Street Corp increased its position in shares of Editas Medicine by 2.4% in the fourth quarter. TD Asset Management Inc. now owns 33,770 shares of the company's stock valued at $754,000 after buying an additional 2,800 shares during the period. Creative Planning boosted its stake in Editas Medicine by 8,910.9% in the second quarter. Schwab Charles Investment Management Inc. increased its position in shares of Editas Medicine by 8.4% in the first quarter. Also, Director Kevin Bitterman sold 1,000,000 shares of Editas Medicine stock in a transaction dated Monday, May 22nd. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. The transaction was disclosed in a document filed with the SEC, which is available through this link.

In other news, Director Boris Nikolic bought 35,000 shares of the business's stock in a transaction that occurred on Friday, June 2nd. The shares were bought at an average cost of $14.15 per share, for a total transaction of $56,600.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions.

Editas Medicine, Inc. engages in the development and commercialization of genome editting technology. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment.



Like this

Latest


11 August 2017
Fiesta Restaurant Group, Inc. (FRGI) moved with flow of 9.79% on Tuesday
Guggenheim Capital LLC purchased a new stake in shares of Fiesta Restaurant Group during the fourth quarter valued at $225,000. For the past 5 years, the company's revenue has grown -2.8%, while the company's earnings per share has grown -0.7%.

11 August 2017
USA stocks fall on North Korea concerns
The U.S. currency was down 0.4 percent at 109.865 yen JPY= , following a retreat to 109.835, its weakest since mid-June. After the bell, Twenty-First Century Fox (FOXA.O) shares were up 0.7 percent following the release of its results.

11 August 2017
Amazon Wants to Sell Tickets to Your Next Concert, Sporting Event
The company already operates Amazon Tickets overseas , but hasn't launched that business at home in the United States yet. But as an alternative to competing, Amazon has also considered partnering with Ticketmaster on a ticketing effort.

11 August 2017
Trump Says Working With Mueller on Russia Probe, Denies Any Election Collusion
In the 2016 presidential election, then-candidate Trump received approximately 4 percent of the vote in the nation's capital. Trump has long derided Mueller's probe, calling it a " witch hunt " and suggesting his team is "biased".

11 August 2017
Brokers Offer Predictions for Avon Products, Inc.'s Q3 2017 Earnings (AVP)
According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $3.82 on company shares. (AVP) to grow. Zacks Investment Research cut shares of Avon Products from a "hold" rating to a "strong sell" rating in a report on Wednesday.

11 August 2017
Cabot Oil & Gas Corporation (COG) Stake Decreased by Mitchell Group Inc
Pointstate Capital Lp increased Delta Air Lines Inc Del (NYSE:DAL) stake by 106,635 shares to 111,735 valued at $5.50M in 2016Q4. It has underperformed by 15.45% the S&P500.The move comes after 8 months positive chart setup for the $11.48 billion company.

11 August 2017
Government hires outside counsel to begin Trans Mountain pipeline legal challenge
The NDP said without the certificates, the Trans Mountain expansion can not move forward on public land. That's unlikely to happen by mid-September when the company planned to start construction, he added.

11 August 2017
Trump thanks Putin for kicking out diplomats
The Russian president's decision came after Congress overwhelmingly passed new sanctions targeting Russia, Iran and North Korea. Trump said he was thanking Putin because the decision allows the USA government to "cut down our payroll".

11 August 2017
Halle Berry has a mind-blowing secret about X-Men's Storm and Wolverine
Fans had often wondered what it all meant but nobody has spoken up about it until now. The actress just revealed who has been putting the X into sex at the X-Men mansion.

11 August 2017
Ameriprise Financial Inc. Reduces Position in SS&C Technologies Holdings, Inc. (SSNC)
Turtle Creek Asset Management Inc. holds 7.66% of its portfolio in SS&C Technologies Holdings, Inc. for 1.45 million shares. The stock presently has a consensus rating of "Buy" and an average price target of $41.25. (NASDAQ:SSNC) for 21,429 shares.



Recommended